How many drugs treat Peptic reflux disease?

Drug Landscape tracks 4 marketed treatments for Peptic reflux disease (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

What's the most recent regulatory action in Peptic reflux disease?

Most recent: Pepcid — FDA approved.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/peptic-reflux-disease.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Peptic reflux disease — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Peptic reflux disease (disease) competitive landscape: 4 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

4 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Peptic reflux disease, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Nexium	esomeprazole	AstraZeneca	Proton pump inhibitor (PPI)	Potassium-transporting ATPase	2001-02-20
Prilosec	omeprazole	AstraZeneca (originally Astra AB)	Proton pump inhibitor (PPI)	ATP-binding cassette sub-family G member 2, Cytochrome P450 1A2, Cytochrome P450 2C19	1989-09-14
Pepcid	famotidine	Generic (originally Yamanouchi/Merck)	Histamine-2 Receptor Antagonist [EPC]	Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2, Solute carrier family 22 member 2	1986-10-01
Omeprazol	Omeprazol	RenJi Hospital		ATP-binding cassette sub-family G member 2, Cytochrome P450 1A2, Cytochrome P450 2C19

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

2026-05-12 — Pepcid · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 2 drugs in Peptic reflux disease
AstraZeneca · 1 drug in Peptic reflux disease
AstraZeneca (originally Astra AB) · 1 drug in Peptic reflux disease
Generic (originally Yamanouchi/Merck) · 1 drug in Peptic reflux disease
RenJi Hospital · 1 drug in Peptic reflux disease

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Peptic reflux disease:

Cite this brief

Drug Landscape (2026). Peptic reflux disease — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/peptic-reflux-disease. Accessed 2026-06-10.

Peptic reflux disease full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing